文献速递白血病造血干细胞移植与细胞治疗

适配体CAR-T细胞(AdCAR-T)的理性组合靶向可预防急性髓系白血病的抗原逃逸

Rational combinatorial targeting by adapter CAR-T-cells (AdCAR-T) prevents antigen escape in acute myeloid leukemia.
PubMed 文献 · Leukemia · 2024-08-03

该研究对30例原发儿童急性髓系白血病(AML)样本进行单细胞抗原表达分析,发现CD33、CD38、CD371、IL1RAP和CD123表达频率最高且异质性大。利用模块化适配体CAR(AdCAR)平台,针对CD33、CD38、CD123、CD135和CD371的适配体分子在体外和体内均显示高效靶向特异性活性。在PDX模型中,理性组合靶向可治愈异质性疾疟,表明组合靶向可预防单靶点CAR-T治疗的抗原逃逸。

要点

  • 儿童AML中CD33、CD38、CD371、IL1RAP和CD123表达频率最高,但患者间及白血病细胞间异质性大。
  • AdCAR-T平台通过适配体分子实现对CAR-T功能的定性和定量控制,对CD33、CD38、CD123、CD135和CD371靶点高效特异。
  • 在PDX模型中,理性组合靶向可治愈异质性疾疟,防止单靶点CAR-T治疗的抗原逃逸。

核心结论

  • 儿童AML抗原表达异质性导致单靶点CAR-T治疗出现抗原逃逸和治疗失败。
  • 利用AdCAR平台的组合靶向是一种精准免疫治疗新概念,在PDX模型中可治愈异质性疾疟。

研究设计与样本

  • 研究对30例原发儿童AML样本进行单细胞抗原表达分析。
  • 利用模块化AdCAR平台生成针对CD33、CD38、CD123、CD135和CD371的适配体分子,并在体外和体内及PDX模型中评估。

主要发现

  • CD33、CD38、CD371、IL1RAP和CD123是30例原发儿童AML样本中最频繁表达的抗原。
  • 抗原高变异性见于不同患者样本间及同一患者白血病细胞间。
  • 新生成的针对CD33、CD38、CD123、CD135和CD371的适配体分子在体外和体内均显示高效靶向特异性活性。
  • 固有瘤内抗原表达异质性导致单靶点CAR-T治疗出现抗原逃逸和治疗失败。
  • 在PDX模型中,AdCAR-T细胞理性组合靶向可治愈异质性疾疟。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Targeting AML by chimeric antigen receptor T-cells (CAR-T) is challenging due to the promiscuous expression of AML-associated antigens in healthy hematopoiesis and high degree of inter- and intratumoral heterogeneity. Here, we present single-cell expression data of AML-associated antigens in 30 primary pediatric AML samples. We identified CD33, CD38, CD371, IL1RAP and CD123 as the most frequently expressed. Notably, high variability was observed not only across the different patient samples but also among leukemic cells of the same patient suggesting the necessity of multiplexed targeting approaches. To address this need, we utilized our modular Adapter CAR (AdCAR) platform, enabling precise qualitative and quantitative control over CAR-T-cell function. We show highly efficient and target-specific activity for newly generated adapter molecules (AMs) against CD33, CD38, CD123, CD135 and CD371, both in vitro and in vivo. We reveal that inherent intratumoral heterogeneity in antigen expression translates into antigen escape and therapy failure to monotargeted CAR-T therapy. Further, we demonstrate in PDX models that rational combinatorial targeting by AdCAR-T-cells can cure heterogenic disease. In conclusion, we elucidate the clinical relevance of heterogeneity in antigen expression in pediatric AML and present a novel concept for precision immunotherapy by combinatorial targeting utilizing the AdCAR platform.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Atar D, Ruoff L, Mast AS, et al. Rational combinatorial targeting by adapter CAR-T-cells (AdCAR-T) prevents antigen escape in acute myeloid leukemia. Leukemia. 2024. PMID: 39095503. doi:10.1038/s41375-024-02351-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。